Overview

Tolerability Study of Trichostatin A In Subjects With Relapsed or Refractory Hematologic Malignancies

Status:
Unknown status
Trial end date:
2020-09-01
Target enrollment:
Participant gender:
Summary
The aim of this study is to investigate the safety and tolerability of trichostatin A in individuals with relapsed or refractory hematologic malignancies.
Phase:
Phase 1
Details
Lead Sponsor:
Vanda Pharmaceuticals
Treatments:
Trichostatin A